Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Post-operative salvage androgen deprivation and radiotherapy for prostate cancer.

D'Amico AV.

Lancet Oncol. 2019 Dec;20(12):1630-1631. doi: 10.1016/S1470-2045(19)30488-7. Epub 2019 Oct 16. No abstract available.

PMID:
31629657
2.

Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.

Fu AZ, Tsai HT, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL.

J Urol. 2017 Jun;197(6):1448-1454. doi: 10.1016/j.juro.2016.12.086. Epub 2016 Dec 19.

3.

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, D'Este C; Trans-Tasman Radiation Oncology Group.

Lancet Oncol. 2005 Nov;6(11):841-50.

PMID:
16257791
4.

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.

Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S.

Lancet Oncol. 2019 Dec;20(12):1740-1749. doi: 10.1016/S1470-2045(19)30486-3. Epub 2019 Oct 16.

PMID:
31629656
5.

Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.

Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.

Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.

PMID:
29229176
6.

Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.

Yoo S, You D, Kim YS, Hong JH, Ahn H, Kim CS.

Urol Int. 2017;99(4):406-413. doi: 10.1159/000481265. Epub 2017 Oct 12.

PMID:
29020683
7.

Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.

Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA.

J Clin Oncol. 2003 Feb 1;21(3):483-9.

PMID:
12560439
8.

Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival.

Abugharib A, Jackson WC, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Zumsteg ZS, Mehra R, Feng FY, Morgan TM, Desai N, Spratt DE.

J Urol. 2017 Mar;197(3 Pt 1):662-668. doi: 10.1016/j.juro.2016.08.106. Epub 2016 Sep 7.

PMID:
27614333
9.

Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery.

Chang JH, Park W, Park JS, Pyo H, Huh SJ, Choi HY, Lee HM, Jeon SS, Seo SI.

Int J Urol. 2015 Jan;22(1):82-7. doi: 10.1111/iju.12604. Epub 2014 Sep 10.

10.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
11.

Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.

Baumann BC, Baumann JC, Christodouleas JP, Soffen E.

Brachytherapy. 2017 Mar - Apr;16(2):291-298. doi: 10.1016/j.brachy.2016.12.011. Epub 2017 Jan 27.

PMID:
28139422
12.

Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging.

Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ.

J Urol. 2018 Mar;199(3):726-733. doi: 10.1016/j.juro.2017.09.033. Epub 2017 Sep 12.

PMID:
28916273
13.

Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.

Kim M, Song C, Jeong IG, Choi SK, Park M, Shim M, Kim YS, You D, Hong JH, Kim CS, Ahn H.

BMC Cancer. 2018 Mar 9;18(1):271. doi: 10.1186/s12885-018-4189-9.

14.

Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.

Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Van Den Eeden SK, Cassidy-Bushrow AE, Zhou Y, Keating NL, Smith MR, Aaronson DS, Potosky AL.

World J Urol. 2016 Dec;34(12):1611-1619. Epub 2016 Apr 15.

15.

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S.

Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6. Erratum in: Lancet Oncol. 2016 Jun;17 (6):e223. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

PMID:
27160475
16.

Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.

Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Inokuchi H, Nakamura K, Kamba T, Inoue T, Kamoto T, Ogawa O, Hiraoka M.

Int J Clin Oncol. 2016 Feb;21(1):148-55. doi: 10.1007/s10147-015-0867-7. Epub 2015 Jul 4.

PMID:
26141133
17.

Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.

Garzotto M, Wajsman Z.

J Urol. 1998 Mar;159(3):950-4; discussion 954-5.

PMID:
9474190
18.

The role of radiotherapy in localised and locally advanced prostate cancer.

Bolla M, Henry A, Mason M, Wiegel T.

Asian J Urol. 2019 Apr;6(2):153-161. doi: 10.1016/j.ajur.2019.02.001. Epub 2019 Feb 8. Review.

19.

Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.

Tiguert R, Rigaud J, Lacombe L, Laverdière J, Fradet Y.

J Urol. 2003 Aug;170(2 Pt 1):447-50.

PMID:
12853796
20.

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodríguez MA, Macias V, Pedro Olive A, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Villà S, Perez de la Haza A, Calvo FA.

Lancet Oncol. 2015 Mar;16(3):320-7. doi: 10.1016/S1470-2045(15)70045-8. Epub 2015 Feb 19. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.

PMID:
25702876

Supplemental Content

Support Center